FERMT2: Unlocking The Potential of A Multi-Tissue Protein as A Drug Target
![Review Report on FERMT2 Target / Biomarker](https://silexon.ai/img/target-biomarker-review.jpg?a=1)
![Content of Review Report on FERMT2 Target / Biomarker](https://silexon.ai/img/target-biomarker-review-content.jpg?a=2)
FERMT2: Unlocking The Potential of A Multi-Tissue Protein as A Drug Target
FERMT2, also known as Fermitin family homolog 2 (isoform 2), is a protein that is expressed in a variety of tissues, including muscle, heart, and brain. It is a member of the Fermitin family, which is characterized by the presence of a unique transmembrane domain and a unique intracellular localization.
FERMT2 is known for its role in cell signaling, particularly in the regulation of cell adhesion and migration. It is a protein that can interact with a variety of intracellular signaling pathways, including the TGF-β pathway and the Wnt pathway.
One of the unique features of FERMT2 is its ability to form a complex with the protein F-actinin. This complex plays a role in regulating cell adhesion and can also act as a biomarker for certain diseases.
FERMT2 has also been shown to be involved in the regulation of cell cycle progression. It has been shown to play a role in the G1 phase of the cell cycle and has been shown to interact with the protein p21.
FERMT2 has also been shown to be involved in the regulation of cell survival. It has been shown to play a role in the regulation of cell apoptosis and has been shown to interact with the protein Bcl-2.
In addition to its role in cell signaling, FERMT2 has also been shown to have potential as a drug target. Several studies have shown that FERMT2 can be targeted by small molecules and have been shown to be sensitive to inhibition.
One of the potential drug targets for FERMT2 is the protein F-actinin. F-actinin is a protein that can interact with FERMT2 and has been shown to play a role in the regulation of cell adhesion. It is possible that a drug that inhibits F-actinin activity could be effective in treating certain diseases where FERMT2 is involved in the regulation of cell adhesion.
Another potential drug target for FERMT2 is the protein p21. P21 is a protein that is often involved in the regulation of cell apoptosis and has been shown to interact with FERMT2. It is possible that a drug that inhibits the activity of p21 could be effective in treating certain diseases where FERMT2 is involved in the regulation of cell apoptosis.
In conclusion, FERMT2 is a protein that is expressed in a variety of tissues and is involved in a number of important cellular processes. Its role in cell signaling and its potential as a drug target make it an attractive target for further research. Further studies are needed to fully understand the role of FERMT2 in cell signaling and its potential as a drug.
Protein Name: FERM Domain Containing Kindlin 2
Functions: Scaffolding protein that enhances integrin activation mediated by TLN1 and/or TLN2, but activates integrins only weakly by itself. Binds to membranes enriched in phosphoinositides. Enhances integrin-mediated cell adhesion onto the extracellular matrix and cell spreading; this requires both its ability to interact with integrins and with phospholipid membranes. Required for the assembly of focal adhesions. Participates in the connection between extracellular matrix adhesion sites and the actin cytoskeleton and also in the orchestration of actin assembly and cell shape modulation. Recruits FBLIM1 to focal adhesions. Plays a role in the TGFB1 and integrin signaling pathways. Stabilizes active CTNNB1 and plays a role in the regulation of transcription mediated by CTNNB1 and TCF7L2/TCF4 and in Wnt signaling
The "FERMT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FERMT2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR) | Fibronectin Type III Domain | FICD | FIG4 | FIGLA | FIGN | FIGNL1 | FIGNL2 | FILIP1